NuVasive Benefits from International Recovery in 1Q21

NuVasive logo

NuVasive reported 1Q21 orthopedic revenue of USD $271.2 million, +4.4% vs. 1Q20. Compared to the first quarter of 2019, sales declined -1.3%. However, the company remains confident in full-year revenue growth above 2019 given March’s better-than-expected recovery that continued into the second quarter. NuVasive expects $1.2 billion in 2021...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us